Literature DB >> 17660346

Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma.

Kadri Altundag, Didem S Dede, Tugrul Purnak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17660346      PMCID： PMC1994514          DOI： 10.1136/jcp.2006.042481

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  4 in total

1.  Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Authors:  Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

3.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Authors:  Socorro María Rodríguez Pinilla; Emiliano Honrado; David Hardisson; Javier Benítez; José Palacios
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

4.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

Authors:  S Banerjee; J S Reis-Filho; S Ashley; D Steele; A Ashworth; S R Lakhani; I E Smith
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411
  4 in total
  1 in total

Review 1.  Targeted nanotechnology for cancer imaging.

Authors:  Randall Toy; Lisa Bauer; Christopher Hoimes; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2014-08-09       Impact factor: 15.470
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.